Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0UO9R
|
|||
| Drug Name |
RGX-202
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Gastrointestinal cancer [ICD-11: 2C11] | Phase 1 | [1] | |
| Company |
Rgenix
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Solute carrier family 6 member 8 (SLC6A8) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03597581) A Study of RGX-202-01 as a Single Agent and as Combination Therapy in Patients With Advanced Gastrointestinal Malignancies. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Rgenix. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.